PMC:7321036 / 55833-56724 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T286","span":{"begin":69,"end":83},"obj":"Disease"},{"id":"T287","span":{"begin":77,"end":83},"obj":"Disease"},{"id":"T288","span":{"begin":168,"end":182},"obj":"Disease"},{"id":"T289","span":{"begin":272,"end":294},"obj":"Disease"},{"id":"T291","span":{"begin":278,"end":294},"obj":"Disease"},{"id":"T292","span":{"begin":286,"end":294},"obj":"Disease"},{"id":"T293","span":{"begin":379,"end":387},"obj":"Disease"},{"id":"T294","span":{"begin":870,"end":878},"obj":"Disease"},{"id":"T295","span":{"begin":881,"end":890},"obj":"Disease"}],"attributes":[{"id":"A286","pred":"mondo_id","subj":"T286","obj":"http://purl.obolibrary.org/obo/MONDO_0008170"},{"id":"A287","pred":"mondo_id","subj":"T287","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A288","pred":"mondo_id","subj":"T288","obj":"http://purl.obolibrary.org/obo/MONDO_0004994"},{"id":"A289","pred":"mondo_id","subj":"T289","obj":"http://purl.obolibrary.org/obo/MONDO_0015667"},{"id":"A290","pred":"mondo_id","subj":"T289","obj":"http://purl.obolibrary.org/obo/MONDO_0018874"},{"id":"A291","pred":"mondo_id","subj":"T291","obj":"http://purl.obolibrary.org/obo/MONDO_0004643"},{"id":"A292","pred":"mondo_id","subj":"T292","obj":"http://purl.obolibrary.org/obo/MONDO_0005059"},{"id":"A293","pred":"mondo_id","subj":"T293","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A294","pred":"mondo_id","subj":"T294","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A295","pred":"mondo_id","subj":"T295","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Ralimetinib is currently in phase 2 clinical trials for treatment of ovarian cancer (Patnaik et al., 2016), and ARRY-797 is in phase 3 clinical trials for treatment of cardiomyopathy. The antiviral activity observed for gilteritinib, an FDA-approved drug for treatment of acute myeloid leukemia, is supported by involvement of another AXL inhibitor, bencentinib, in the RECOVERY COVID-19 clinical trial in the United Kingdom. AXL is known to regulate various intracellular signaling pathways (Allen et al., 2002; Hafizi and Dahlbäck 2006), including Ras/ERK, PI3K, and p38 (Allen et al., 2002); AXL inhibition here may contribute to the downregulation of p38 signaling. Apilimod, a PIKFYVE inhibitor, has been described in a recent study to have antiviral capacity (Ou et al., 2020). Here we expand this into a mechanism of regulation by phosphorylation of PIKFYVE upon SARS-CoV-2 infection."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T739","span":{"begin":198,"end":206},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T740","span":{"begin":473,"end":482},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T741","span":{"begin":659,"end":668},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T742","span":{"begin":680,"end":681},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T743","span":{"begin":701,"end":704},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T744","span":{"begin":723,"end":724},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T745","span":{"begin":809,"end":810},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Ralimetinib is currently in phase 2 clinical trials for treatment of ovarian cancer (Patnaik et al., 2016), and ARRY-797 is in phase 3 clinical trials for treatment of cardiomyopathy. The antiviral activity observed for gilteritinib, an FDA-approved drug for treatment of acute myeloid leukemia, is supported by involvement of another AXL inhibitor, bencentinib, in the RECOVERY COVID-19 clinical trial in the United Kingdom. AXL is known to regulate various intracellular signaling pathways (Allen et al., 2002; Hafizi and Dahlbäck 2006), including Ras/ERK, PI3K, and p38 (Allen et al., 2002); AXL inhibition here may contribute to the downregulation of p38 signaling. Apilimod, a PIKFYVE inhibitor, has been described in a recent study to have antiviral capacity (Ou et al., 2020). Here we expand this into a mechanism of regulation by phosphorylation of PIKFYVE upon SARS-CoV-2 infection."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T33558","span":{"begin":188,"end":197},"obj":"Chemical"},{"id":"T5587","span":{"begin":220,"end":232},"obj":"Chemical"},{"id":"T16731","span":{"begin":250,"end":254},"obj":"Chemical"},{"id":"T55232","span":{"begin":335,"end":348},"obj":"Chemical"},{"id":"T55122","span":{"begin":339,"end":348},"obj":"Chemical"},{"id":"T58497","span":{"begin":690,"end":699},"obj":"Chemical"},{"id":"T21382","span":{"begin":746,"end":755},"obj":"Chemical"}],"attributes":[{"id":"A93329","pred":"chebi_id","subj":"T33558","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A2651","pred":"chebi_id","subj":"T5587","obj":"http://purl.obolibrary.org/obo/CHEBI_145372"},{"id":"A88680","pred":"chebi_id","subj":"T16731","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A68298","pred":"chebi_id","subj":"T55232","obj":"http://purl.obolibrary.org/obo/CHEBI_62434"},{"id":"A80740","pred":"chebi_id","subj":"T55122","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A18029","pred":"chebi_id","subj":"T58497","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A82407","pred":"chebi_id","subj":"T21382","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Ralimetinib is currently in phase 2 clinical trials for treatment of ovarian cancer (Patnaik et al., 2016), and ARRY-797 is in phase 3 clinical trials for treatment of cardiomyopathy. The antiviral activity observed for gilteritinib, an FDA-approved drug for treatment of acute myeloid leukemia, is supported by involvement of another AXL inhibitor, bencentinib, in the RECOVERY COVID-19 clinical trial in the United Kingdom. AXL is known to regulate various intracellular signaling pathways (Allen et al., 2002; Hafizi and Dahlbäck 2006), including Ras/ERK, PI3K, and p38 (Allen et al., 2002); AXL inhibition here may contribute to the downregulation of p38 signaling. Apilimod, a PIKFYVE inhibitor, has been described in a recent study to have antiviral capacity (Ou et al., 2020). Here we expand this into a mechanism of regulation by phosphorylation of PIKFYVE upon SARS-CoV-2 infection."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T416","span":{"begin":459,"end":491},"obj":"http://purl.obolibrary.org/obo/GO_0035556"},{"id":"T417","span":{"begin":473,"end":482},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T418","span":{"begin":559,"end":563},"obj":"http://purl.obolibrary.org/obo/GO_0016303"},{"id":"T419","span":{"begin":659,"end":668},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T420","span":{"begin":824,"end":853},"obj":"http://purl.obolibrary.org/obo/GO_0042325"},{"id":"T421","span":{"begin":824,"end":834},"obj":"http://purl.obolibrary.org/obo/GO_0065007"},{"id":"T422","span":{"begin":838,"end":853},"obj":"http://purl.obolibrary.org/obo/GO_0016310"}],"text":"Ralimetinib is currently in phase 2 clinical trials for treatment of ovarian cancer (Patnaik et al., 2016), and ARRY-797 is in phase 3 clinical trials for treatment of cardiomyopathy. The antiviral activity observed for gilteritinib, an FDA-approved drug for treatment of acute myeloid leukemia, is supported by involvement of another AXL inhibitor, bencentinib, in the RECOVERY COVID-19 clinical trial in the United Kingdom. AXL is known to regulate various intracellular signaling pathways (Allen et al., 2002; Hafizi and Dahlbäck 2006), including Ras/ERK, PI3K, and p38 (Allen et al., 2002); AXL inhibition here may contribute to the downregulation of p38 signaling. Apilimod, a PIKFYVE inhibitor, has been described in a recent study to have antiviral capacity (Ou et al., 2020). Here we expand this into a mechanism of regulation by phosphorylation of PIKFYVE upon SARS-CoV-2 infection."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T12","span":{"begin":69,"end":83},"obj":"Phenotype"},{"id":"T13","span":{"begin":168,"end":182},"obj":"Phenotype"},{"id":"T14","span":{"begin":272,"end":294},"obj":"Phenotype"}],"attributes":[{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0100615"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0001638"},{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0004808"}],"text":"Ralimetinib is currently in phase 2 clinical trials for treatment of ovarian cancer (Patnaik et al., 2016), and ARRY-797 is in phase 3 clinical trials for treatment of cardiomyopathy. The antiviral activity observed for gilteritinib, an FDA-approved drug for treatment of acute myeloid leukemia, is supported by involvement of another AXL inhibitor, bencentinib, in the RECOVERY COVID-19 clinical trial in the United Kingdom. AXL is known to regulate various intracellular signaling pathways (Allen et al., 2002; Hafizi and Dahlbäck 2006), including Ras/ERK, PI3K, and p38 (Allen et al., 2002); AXL inhibition here may contribute to the downregulation of p38 signaling. Apilimod, a PIKFYVE inhibitor, has been described in a recent study to have antiviral capacity (Ou et al., 2020). Here we expand this into a mechanism of regulation by phosphorylation of PIKFYVE upon SARS-CoV-2 infection."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1261","span":{"begin":335,"end":338},"obj":"Gene"},{"id":"1262","span":{"begin":426,"end":429},"obj":"Gene"},{"id":"1263","span":{"begin":554,"end":557},"obj":"Gene"},{"id":"1264","span":{"begin":569,"end":572},"obj":"Gene"},{"id":"1265","span":{"begin":595,"end":598},"obj":"Gene"},{"id":"1266","span":{"begin":655,"end":658},"obj":"Gene"},{"id":"1267","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"1268","span":{"begin":220,"end":232},"obj":"Chemical"},{"id":"1269","span":{"begin":350,"end":361},"obj":"Chemical"},{"id":"1270","span":{"begin":670,"end":678},"obj":"Chemical"},{"id":"1271","span":{"begin":69,"end":83},"obj":"Disease"},{"id":"1272","span":{"begin":168,"end":182},"obj":"Disease"},{"id":"1273","span":{"begin":272,"end":294},"obj":"Disease"},{"id":"1274","span":{"begin":379,"end":387},"obj":"Disease"},{"id":"1275","span":{"begin":870,"end":890},"obj":"Disease"}],"attributes":[{"id":"A1261","pred":"tao:has_database_id","subj":"1261","obj":"Gene:558"},{"id":"A1262","pred":"tao:has_database_id","subj":"1262","obj":"Gene:558"},{"id":"A1263","pred":"tao:has_database_id","subj":"1263","obj":"Gene:5594"},{"id":"A1264","pred":"tao:has_database_id","subj":"1264","obj":"Gene:5594"},{"id":"A1265","pred":"tao:has_database_id","subj":"1265","obj":"Gene:558"},{"id":"A1266","pred":"tao:has_database_id","subj":"1266","obj":"Gene:5594"},{"id":"A1268","pred":"tao:has_database_id","subj":"1268","obj":"MESH:C000609080"},{"id":"A1270","pred":"tao:has_database_id","subj":"1270","obj":"MESH:C504227"},{"id":"A1271","pred":"tao:has_database_id","subj":"1271","obj":"MESH:D010051"},{"id":"A1272","pred":"tao:has_database_id","subj":"1272","obj":"MESH:D009202"},{"id":"A1273","pred":"tao:has_database_id","subj":"1273","obj":"MESH:D015470"},{"id":"A1274","pred":"tao:has_database_id","subj":"1274","obj":"MESH:C000657245"},{"id":"A1275","pred":"tao:has_database_id","subj":"1275","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Ralimetinib is currently in phase 2 clinical trials for treatment of ovarian cancer (Patnaik et al., 2016), and ARRY-797 is in phase 3 clinical trials for treatment of cardiomyopathy. The antiviral activity observed for gilteritinib, an FDA-approved drug for treatment of acute myeloid leukemia, is supported by involvement of another AXL inhibitor, bencentinib, in the RECOVERY COVID-19 clinical trial in the United Kingdom. AXL is known to regulate various intracellular signaling pathways (Allen et al., 2002; Hafizi and Dahlbäck 2006), including Ras/ERK, PI3K, and p38 (Allen et al., 2002); AXL inhibition here may contribute to the downregulation of p38 signaling. Apilimod, a PIKFYVE inhibitor, has been described in a recent study to have antiviral capacity (Ou et al., 2020). Here we expand this into a mechanism of regulation by phosphorylation of PIKFYVE upon SARS-CoV-2 infection."}

{"project":"LitCovid-sentences","denotations":[{"id":"T361","span":{"begin":0,"end":183},"obj":"Sentence"},{"id":"T362","span":{"begin":184,"end":425},"obj":"Sentence"},{"id":"T363","span":{"begin":426,"end":669},"obj":"Sentence"},{"id":"T364","span":{"begin":670,"end":783},"obj":"Sentence"},{"id":"T365","span":{"begin":784,"end":891},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Ralimetinib is currently in phase 2 clinical trials for treatment of ovarian cancer (Patnaik et al., 2016), and ARRY-797 is in phase 3 clinical trials for treatment of cardiomyopathy. The antiviral activity observed for gilteritinib, an FDA-approved drug for treatment of acute myeloid leukemia, is supported by involvement of another AXL inhibitor, bencentinib, in the RECOVERY COVID-19 clinical trial in the United Kingdom. AXL is known to regulate various intracellular signaling pathways (Allen et al., 2002; Hafizi and Dahlbäck 2006), including Ras/ERK, PI3K, and p38 (Allen et al., 2002); AXL inhibition here may contribute to the downregulation of p38 signaling. Apilimod, a PIKFYVE inhibitor, has been described in a recent study to have antiviral capacity (Ou et al., 2020). Here we expand this into a mechanism of regulation by phosphorylation of PIKFYVE upon SARS-CoV-2 infection."}

{"project":"2_test","denotations":[{"id":"32645325-26581242-20773093","span":{"begin":101,"end":105},"obj":"26581242"},{"id":"32645325-11756555-20773094","span":{"begin":507,"end":511},"obj":"11756555"},{"id":"32645325-16737840-20773095","span":{"begin":533,"end":537},"obj":"16737840"},{"id":"32645325-11756555-20773096","span":{"begin":588,"end":592},"obj":"11756555"},{"id":"32645325-32221306-20773097","span":{"begin":777,"end":781},"obj":"32221306"}],"text":"Ralimetinib is currently in phase 2 clinical trials for treatment of ovarian cancer (Patnaik et al., 2016), and ARRY-797 is in phase 3 clinical trials for treatment of cardiomyopathy. The antiviral activity observed for gilteritinib, an FDA-approved drug for treatment of acute myeloid leukemia, is supported by involvement of another AXL inhibitor, bencentinib, in the RECOVERY COVID-19 clinical trial in the United Kingdom. AXL is known to regulate various intracellular signaling pathways (Allen et al., 2002; Hafizi and Dahlbäck 2006), including Ras/ERK, PI3K, and p38 (Allen et al., 2002); AXL inhibition here may contribute to the downregulation of p38 signaling. Apilimod, a PIKFYVE inhibitor, has been described in a recent study to have antiviral capacity (Ou et al., 2020). Here we expand this into a mechanism of regulation by phosphorylation of PIKFYVE upon SARS-CoV-2 infection."}